Bruceine A protects against diabetic kidney disease via inhibiting galectin-1

Kidney Int. 2022 Sep;102(3):521-535. doi: 10.1016/j.kint.2022.04.020. Epub 2022 May 19.

Abstract

Bruceine A is a natural quassinoid compound extracted from the fruit of the Traditional Chinese Medicine Brucea javanica (L.) Merr. that has various types of various biological activities. However, whether the compound has a protective effect on diabetic kidney disease remains unknown. Galectin-1 is actively involved in a variety of chronic inflammation-relevant human diseases including diabetic kidney disease. Here, we identified Bruceine A as a kidney protective molecule against a model of diabetic kidney disease in db/db mice with potent anti-inflammatory activity both in vitro and in vivo. Mechanistically, by selectively binding to the conserved carbohydrate-recognition domain of galectin-1 and disrupting the interaction between galectin-1 and the receptor for activated protein C kinase 1, Bruceine A was found to inhibit galectin-1-mediated inflammatory signal transduction under high glucose stress in rat mesangial HBZY-1 cells. Thus, our findings reveal Bruceine A as an unidentified galectin-1 inhibitor affording significant protection against diabetic kidney disease and may provide novel pharmacological therapeutics for the disease.

Keywords: Bruceine A; RACK1; diabetic kidney disease; galectin-1; inflammation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Diabetes Mellitus*
  • Diabetic Nephropathies* / drug therapy
  • Diabetic Nephropathies* / etiology
  • Diabetic Nephropathies* / prevention & control
  • Galectin 1
  • Humans
  • Mice
  • Quassins* / chemistry
  • Quassins* / pharmacology
  • Rats

Substances

  • Galectin 1
  • Quassins
  • bruceine A